Rafter Natasha, Connor Jennie, Hall Jason, Jackson Rod, Martin Isobel, Parag Varsha, Vander Hoorn Stephen, Rodgers Anthony
Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand.
N Z Med J. 2005 Oct 7;118(1223):U1676.
To measure the use of three major types of cardiovascular medications (antiplatelet, blood pressure lowering, and cholesterol lowering) in primary care, and their level of targeting to individuals at high absolute risk of a cardiovascular event.
Demographic, risk factor, and prescribing data from the Dunedin Royal New Zealand College of General Practitioners Research Unit database were analysed. The data set consisted of 25,384 individuals, men aged at least 45 years and women at least 55 years, who consulted a doctor in 2000 in a practice which supplied electronic clinical notes. People with congestive heart failure were excluded. Five-year risk of a cardiovascular event was estimated using a history of vascular disease or the Framingham risk equation, and correlated with prescribed medications.
Cardiovascular risk could be estimated for only one-third of the study population due to missing risk factor information. Data were largely unavailable on antiplatelet agents and so lipid lowering and blood pressure lowering medications were used to assess the 'treatment gap'. This combination was prescribed to only 28% of those with documented cardiovascular disease. For the remainder without a history of disease and for whom 5-year absolute risk of cardiovascular disease could be estimated, prescription of combination therapy ranged from 8% in the lowest risk group (<5% 5-year risk) to 14-16% in the other risk categories.
Among this primary care population, more than two-thirds of people with vascular disease were not receiving guideline-recommended medications and there was little evidence of targeting by absolute risk for those without disease. However limited conclusions can be made for the latter group because of lack of documented risk factor information. While these treatment gaps may be less now, for example due to increased access to statins, it is probable that substantial gaps remain.
评估在初级医疗保健中三种主要类型心血管药物(抗血小板药物、降压药物和降脂药物)的使用情况,以及这些药物针对心血管事件绝对风险较高个体的靶向治疗水平。
对来自新西兰达尼丁皇家全科医生学院研究单位数据库的人口统计学、风险因素和处方数据进行分析。数据集包括25384名个体,年龄至少45岁的男性和至少55岁的女性,他们于2000年在提供电子临床记录的医疗机构就诊。排除充血性心力衰竭患者。使用血管疾病史或弗明汉风险方程估算心血管事件的五年风险,并将其与所开药物相关联。
由于缺少风险因素信息,仅能对三分之一的研究人群估算心血管风险。抗血小板药物的数据大多无法获取,因此使用降脂和降压药物来评估“治疗缺口”。在有心血管疾病记录的人群中,仅有28%的人使用了这种联合治疗。对于其余无疾病史且可估算心血管疾病五年绝对风险的人群,联合治疗的处方率在最低风险组(五年风险<5%)为8%,在其他风险类别中为14% - 16%。
在这一初级医疗保健人群中,超过三分之二的血管疾病患者未接受指南推荐的药物治疗,对于无疾病的人群,几乎没有证据表明根据绝对风险进行靶向治疗。然而,由于缺乏记录的风险因素信息,对于后一组人群只能得出有限的结论。虽然这些治疗缺口现在可能有所减少,例如由于他汀类药物的可及性增加,但很可能仍存在较大缺口。